NMN vs NR: Bioavailability and Efficacy Compared

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two most widely studied NAD+ precursors. Both enter the NAD+ biosynthesis salvage pathway, but they do so at different points and via different transporters. Understanding these distinctions is important for clinicians evaluating which precursor may be most appropriate for their practice.

Biochemical Pathways

NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2), and NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1-3). NMN therefore sits one enzymatic step closer to NAD+ in the salvage pathway.

A critical discovery by Grozio et al. (2019), published in Nature Metabolism, identified a dedicated NMN transporter — Slc12a8 — expressed in the small intestine and other tissues. This finding overturned the previous assumption that NMN must first be dephosphorylated to NR before cellular uptake, demonstrating instead that NMN can be directly transported into cells.

Preclinical Comparisons

Head-to-head preclinical studies are limited, but the available evidence provides useful comparisons. Trammell et al. (2016) published the first human pharmacokinetic study of NR in Nature Communications, demonstrating that oral NR supplementation (up to 1000 mg/day) dose-dependently increased blood NAD+ levels in healthy volunteers.

For NMN, Mills et al. (2016) demonstrated robust NAD+ elevation and broad anti-aging effects in mice with long-term supplementation. Subsequent human trials, including the randomised controlled trial by Yi et al. (2023), confirmed that oral NMN (300–600 mg/day) safely elevated blood NAD+ in middle-aged adults.

Stability Considerations

From a pharmaceutical standpoint, NMN and NR differ in chemical stability. NR is known to be relatively unstable and sensitive to heat, light, and moisture, often requiring specialised formulation (such as chloride salt forms) to maintain shelf stability. NMN, by contrast, demonstrates greater inherent stability, which may be advantageous for formulation and storage in clinical settings.

Route of Administration

Both NMN and NR are predominantly studied as oral supplements. However, NMN's direct conversion to NAD+ (requiring only the NMNAT step) and its demonstrated direct cellular uptake via Slc12a8 make it a particularly compelling candidate for injectable formulations, where bypassing gut degradation entirely would maximise bioavailability.

For injectable applications, NMN's stability profile and proximity to NAD+ in the biosynthetic pathway present practical advantages over NR, though direct clinical comparisons of injectable NMN versus injectable NR have not yet been published.

Summary

• Both NMN and NR effectively elevate NAD+ levels in human studies
• NMN sits one enzymatic step closer to NAD+ in the salvage pathway
• NMN has a dedicated cellular transporter (Slc12a8) enabling direct uptake
• NMN demonstrates greater chemical stability than NR
• Direct head-to-head human trials are still needed for definitive comparison